Seattle, United States
Blaze Bioscience is a biotechnology company founded in 2010 and headquartered in the United States. The company's mission, as captured in its slogan "Dedicated to improving the lives of cancer patients," reflects its commitment to leveraging innovative technology to positively impact the lives of cancer patients, particularly children undergoing brain cancer surgery.
With their proprietary Tumor Paint technology®, including the CANVAS Imaging system® and the CDP Discovery Platform, Blaze Bioscience aims to revolutionize the detection, removal, and treatment of cancer, making it sensitive, reliable, and accessible. The focus on early-stage cancers, where a cure may still be possible, underscores the company's dedication to improving patient outcomes.
The company's recent $20.23M Venture Round investment in 01 February 2019 further underscores investor confidence in Blaze Bioscience's potential to drive meaningful change in the biotechnology and healthcare industries. While the specific investors behind this round are not provided, the substantial investment speaks to the promising nature of the company's work.
-logo.jpg "Foresight Diagnostics (a Natera company)"){kind=logo}
